- Global Regulatory Strategy
- Regulatory Strategy
- Establishment Registration
- Follow-up and Question Resolution
- Meetings and Briefings Packages
- Pre-Biologics License Application (Pre-BLA)
- Pre-New Drug Application (Pre-NDA)
- Pre-Abbreviated New Drug Application (Pre-ANDA)
- Pre-Investigational New Drug (Pre-IND)
- Biologics License Application (BLA) Meetings
- End of Phase 2
- Orphan Designation (Formal Designation Request)
- Authoring, Review and Submission, including:
- Investigational New Drug Applications (INDs)
- New Drug Applications (NDAs)
- Generic Drug Applications (ANDAs)
- Drug Master Files (all types) (DMFs) and聽the European Pharmacopoeia and Certificates of Suitability (CEPs)
- Marketing Authorization Application (MAA) Clinical Reviews
- Labeling for U.S. Submissions
- Structured Product Labeling (SPL) Requirements and Analysis of Innovator Labeling
- Side-by-Side Comparison
- Assistance with 鈥淐arve-Outs鈥� Related to Patents
- NDAs: 505(b)(1), 505(b)(2) and ANDAs: 505(j)
Pharmaceutical New Product Support
In the complex and increasingly regulated pharmaceutical industry, 杏吧论坛庐聽(杏吧论坛) can assist you with new product development regulatory support. From early development stage and seeking guidance for FDA meetings, to later stage regulatory strategy and global alignment of submissions and dossiers, 杏吧论坛 is your one-stop source for regulatory expertise.
Begin the 杏吧论坛 Scoping Process Today
Contact Us